TABLE 1

Plasma levels of several parameters in SD rats treated with MG

ParameterControlMGMG + BSOBSOMG + ALAALA
Body weight (g)558 ± 18556 ± 9582 ± 13536 ± 33588 ± 7543 ± 21
Fasting plasma glucose (mg/dL)89 ± 6121 ± 6*139 ± 7***116 ± 10*95 ± 989 ± 8
Fasting plasma insulin (μg/L)1.2 ± 0.10.5 ± 0.1**0.3 ± 0.02***0.7 ± 0.1*1 ± 0.21.25 ± 0.06
Plasma free fatty acids (μg/L)393 ± 41619 ± 21***890 ± 21***†††601 ± 32***405 ± 20†††389 ± 22†††
Total cholesterol (mmol/L)1.8 ± 0.12.4 ± 0.05***2.8 ± 0.05***††2.1 ± 0.1**‡‡‡1.9 ± 0.03††
HDL (mmol/L)1.2 ± 0.050.7 ± 0.06**0.46 ± 0.05***0.78 ± 0.1**‡1.0 ± 0.07
Triglycerides (mmol/L)0.2 ± 0.030.5 ± 0.04***0.7 ± 0.02***††0.4 ± 0.05**‡‡‡0.3 ± 0.02††
Creatinine (μmol/L)55 ± 566 ± 675 ± 858 ± 552 ± 2
CK (U/L)315 ± 20365 ± 25378 ± 23355 ± 21332 ± 15
ALT (U/L)60 ± 1065 ± 971 ± 1063 ± 759 ± 8
AST (U/L)46 ± 550 ± 856 ± 948 ± 445 ± 6
  • Values are means ± SE of n = 6 experiments. Either 0.9% saline or MG (60 mg/kg/day) was delivered by continuous infusion with a subcutaneous osmotic pump for 28 days to all groups of rats (n = 6 each). The MG scavenger ALA (30 mg/kg/day in drinking water; MG + ALA and ALA) or GSH synthesis inhibitor BSO (30 mg/kg/day in drinking water; MG + BSO and BSO) was administered to some groups of rats. The control group received only saline (0.9% by pump). After 28 days, basal fasting plasma levels of substances listed in the table were measured.

  • *P < 0.05, **P < 0.01, ***P < 0.001 vs. respective control group;

  • P < 0.05, ††P < 0.01, †††P < 0.001 vs. respective MG group; ‡P < 0.05, ‡‡‡P < 0.001 vs. respective MG + BSO group.